|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DHX57 |
Gene summary for DHX57 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DHX57 | Gene ID | 90957 |
| Gene name | DExH-box helicase 57 | |
| Gene Alias | DDX57 | |
| Cytomap | 2p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q6P158 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 90957 | DHX57 | HCC1_Meng | Human | Liver | HCC | 2.45e-39 | 1.93e-02 | 0.0246 |
| 90957 | DHX57 | HCC2_Meng | Human | Liver | HCC | 4.12e-09 | 4.62e-03 | 0.0107 |
| 90957 | DHX57 | HCC2 | Human | Liver | HCC | 3.92e-02 | 1.36e+00 | 0.5341 |
| 90957 | DHX57 | HCC5 | Human | Liver | HCC | 2.37e-13 | 4.90e-01 | 0.4932 |
| 90957 | DHX57 | S014 | Human | Liver | HCC | 8.58e-04 | 2.70e-01 | 0.2254 |
| 90957 | DHX57 | S015 | Human | Liver | HCC | 4.40e-04 | 3.43e-01 | 0.2375 |
| 90957 | DHX57 | S016 | Human | Liver | HCC | 4.78e-10 | 3.82e-01 | 0.2243 |
| 90957 | DHX57 | S027 | Human | Liver | HCC | 1.29e-06 | 5.05e-01 | 0.2446 |
| 90957 | DHX57 | S029 | Human | Liver | HCC | 1.10e-04 | 3.21e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DHX57 | SNV | Missense_Mutation | rs370897825 | c.259N>T | p.Arg87Cys | p.R87C | Q6P158 | protein_coding | deleterious(0) | benign(0.249) | TCGA-A5-A0GW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DHX57 | SNV | Missense_Mutation | rs140333800 | c.2251N>T | p.Arg751Trp | p.R751W | Q6P158 | protein_coding | deleterious(0) | benign(0.146) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| DHX57 | SNV | Missense_Mutation | novel | c.1177N>A | p.Leu393Ile | p.L393I | Q6P158 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DHX57 | SNV | Missense_Mutation | rs374119423 | c.1837N>A | p.Val613Ile | p.V613I | Q6P158 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-AJ-A3OK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| DHX57 | SNV | Missense_Mutation | c.2992N>T | p.Pro998Ser | p.P998S | Q6P158 | protein_coding | tolerated(0.07) | probably_damaging(0.994) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DHX57 | SNV | Missense_Mutation | c.495A>C | p.Glu165Asp | p.E165D | Q6P158 | protein_coding | tolerated(0.45) | benign(0) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD | |
| DHX57 | SNV | Missense_Mutation | rs865861806 | c.3100N>T | p.Arg1034Cys | p.R1034C | Q6P158 | protein_coding | deleterious(0.05) | benign(0.018) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| DHX57 | SNV | Missense_Mutation | novel | c.3023N>C | p.Ile1008Thr | p.I1008T | Q6P158 | protein_coding | tolerated(0.28) | benign(0.155) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DHX57 | SNV | Missense_Mutation | c.1649N>T | p.Arg550Ile | p.R550I | Q6P158 | protein_coding | tolerated(0.13) | probably_damaging(0.962) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DHX57 | SNV | Missense_Mutation | c.4096N>A | p.Leu1366Met | p.L1366M | Q6P158 | protein_coding | deleterious(0) | possibly_damaging(0.833) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |